loader2
Partner With Us NRI

Indoco Remedies Ltd share Price Today

Company details

317.10
330.00
308.30
415.00
6M Return -3.57%
1Y Return -9.07%
Mkt Cap.(Cr) 2,952.59
Volume 145,623
Div Yield 0.47%
OI
-
OI Chg %
-
Volume 145,623

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
About The Stock

    Indoco manufactures and markets branded formulations and APIs for the domestic and export markets. In domestic formulations, through its nine marketing divisions, the company serves a range of specialties (acute heavy).

    • Domestic formulations accounted for 54% of revenues. Major therapies are: respiratory, anti-infectives, stomatologicals, gastrointestinals and vitamins
    • Formulation exports accounted for 41% (regulated markets: 81%) of revenues while APIs contributed 4% with remaining coming from CRAMS
Q3FY23

    Domestic formulations grew 12.2% YoY to ₹ ~204 crore while export formulations expanded 30% YoY to ₹ ~186 crore.

    • Sales were up 11.4% YoY to ₹ 399 crore
    • EBITDA de-grew 16.3% YoY to ₹ 61.5 crore with margins at 15.4%
    • PAT for Q3 was at ₹ 38 crore (down 16.4% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Indoco Remedies announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • During the Q4FY24, revenues of Indoco Remedies grew by 1.7% at Rs 4,351 million, as against Rs 4,280 million, same quarter last year.
  • EBIDTA to net sales for the quarter is 13.2% at Rs 574 million, compared to 15.0% at Rs 642 million, same quarter last year.
  • Profit After Tax to net sales is 8.6% at Rs 376 million, compared to 5.9% at Rs 254 million, same quarter last year.

FY24 Financial Highlights:

  • For the year, revenues grew by 7.6% at Rs 17,619 million, as against Rs 16,381 million, same period last year.
  • EBIDTA to net sales for the period is 14.6% at Rs 2,580 million, compared to 17.4% at Rs 2,849 million, same period last year.
  • Profit After Tax to net sales is 6.6% at Rs 1,166 million, compared to 8.6% at Rs 1,414 million, same period last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “Indoco is set to take a big leap based on the various strategic decisions taken during this year. We are optimistic to improve our performance in the coming quarters.”

Result PDF

View Other Company Results

Indoco Remedies Ltd shares SWOT Analysis

Strengths (4)

  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Book Value per share Improving for last 2 years
  • Company with Zero Promoter Pledge

Weakness (10)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (0)

Data not found

Threats (3)

  • Promoter decreasing their shareholding
  • Increasing Trend in Non-Core Income
  • RSI indicating price weakness

Resistance and support

R1 324.7
R2 327.7
R3 331.4
Pivot

321.00

S1 318.0
S2 314.3
S3 311.3
EMA SMA
328.1
335.9
343.6
347.3
327.6
333.8
353.5
347.8
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
XTX MARKETS LLP Bulk Purchase 2021-08-12 507.94 478901 NSE
XTX MARKETS LLP Bulk Sell 2021-08-12 508.51 481713 NSE
DOVETAIL INDIA FUND CLASS 6 SHARES Bulk Purchase 2020-12-02 265.31 500000 NSE
Name Category Shares
PANANDIKAR ADITI MILIND PROMOTER 6.07%
MADHURA SURESH KARE PROMOTER 5.64%
KARE ARUNA SURESH PROMOTER 5.2%
KARE SURESH GOVIND PROMOTER 4.4%
SPA HOLDINGS PVT LTD PROMOTER 19.89%
SHANTERI INVESTMENT PVT LTD PROMOTER 17.11%

OUR RESEARCH VIEW

Investment recommendation
Call Date
25 Jan 2023
Entry Price 348.00
Target Price 440.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Indoco Remedies Ltd Stocks COMPARISON

Financials( in Cr) Indoco Remedies Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 320.30 1,531.40 1,399.05 1,051.40 3,910.75
% Change -2.21 0.26 -0.54 5.45 0.47
Mcap Cr 2,952.59 367,434.16 112,954.68 105,795.44 103,818.29
Revenue TTM Cr 1,668.61 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 142.25 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 32.91 39.15 26.62 28.83 75.36
1 Year Return -9.07 60.69 51.61 103.07 19.36
ROCE 16.74 16.79 14.76 16.25 19.30
ROE 14.72 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,028.25 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 44,248.95 -31,659.16
LAST 3M 105,886.10 -43,482.14
LAST 6M 173,149.22 48,654.40
LAST 12M 264,707.07 127,969.33
Indoco Remedies Limited - Updates

May 18, 2024 l NSE Announcement

Indoco Remedies Limited - Outcome of Board Meeting

May 17, 2024 l NSE Announcement

Indoco Remedies` APIL Kilo Lab manufacturing unit completes USFDA audit

May 17, 2024 l BSE Announcement

Date Action Type Ratio
Sep 18, 2023 Dividend 112.5
Sep 14, 2022 Dividend 37.5
Sep 14, 2022 Dividend 75

Indoco Remedies Ltd Information

Stock PE (TTM)
32.91
Promoter Holding
58.72%
Book Value
120.4025
ROCE
16.74%
ROE
14.72%
Description
  • Indoco Remedies Ltd. is a fully integrated, research-oriented pharma company. It manufactures and markets Active Pharmaceutical Ingredients (APIs) and Formulations (Finished Dosage Forms). It was incorporated in 1947, with its headquarters in Mumbai. During FY 2021-2022, the company generated a total revenue of Rs 1,543.08 crore, up 23.98% from the previous financial year, 2020-2021. On 31 October 2022, Indoco Remedies Ltd.’s market capitalisation was Rs 3,262 crore.

    The company is listed on the Bombay Stock Exchange with the code 532612, and on the National Stock Exchange with the code INDOCO. It is also listed on the MCX Stock Exchange.

    Indoco Remedies Ltd. has a well-built brand portfolio with a number of products in various therapeutic segments. It includes high-growth lifestyle segments like cardiovascular, musculoskeletal, anti-diabetics, central nervous system, dental care, and nutrition. The company has a strong presence in the international market across 55 countries and employs close to 6000 personnel with more than 300 skilled scientists. It has nine manufacturing facilities, of which three are for APIs and six for finished dosages.

    On 30 June 2022, the company’s shareholding pattern showed a promoter holding of 58.69%, an FII holding of 1.17%, a DII holding of 18.08%, and a public holding of 22.06%. The leading promoter is Spa Holdings Pvt Ltd., with a 19.9% share. In the June 2022 quarter, mutual fund holdings decreased from 17.52% to 17.39%, while FPI holdings increased from 1.15% to 1.17%.

    The company’s board of directors comprises Mr Suresh G Kare, Mr Sundeep V Bambolkar, Mr Rajiv P Kakodkar, Dr Anand Nadkarni, Mr D M Gavaskar, Mr Abhijit Yashwant Gore, Dr (Ms) Vasudha V Kamat, and Ms Aditi Kare Panandikar. The auditors are Gokhale & Sathe. As of 30 June 2022, the company’s total outstanding shares were 9.22 crores.

    On 31 October 2022, the company’s share’s closing price was Rs 353.60 on BSE. On NSE, its closing price was Rs 354. The share touched a 52-week high of Rs 498 and a 52-week low of Rs 307.65. Investors earned a six-month return of -8.63% and a one-year return of -21.40%.

    The company’s peers include Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., and Divis Laboratories Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Indoco House 166 C S T Road, Santacruz (East) Kalina, Mumbai, Maharashtra, 400098

Tel : 91-022-26541851-55
Email : compliance.officer:indoco.com
Website : http://www.indoco.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 532612
NSE Code : INDOCO
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE873D01024

FAQ’s on Indoco Remedies Ltd Shares

You can buy Indoco Remedies Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Indoco Remedies Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:47 PM the closing price of Indoco Remedies Ltd was Rs.320.30.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:47 PM, the market cap of Indoco Remedies Ltd stood at Rs. 2,952.59.

The latest PE ratio of Indoco Remedies Ltd as of May 17, 2024 03:47 PM is 32.91

The latest PB ratio of Indoco Remedies Ltd as of May 17, 2024 03:47 PM is 0.38

The 52-week high of Indoco Remedies Ltd share price is Rs. 415.00 while the 52-week low is Rs. 308.30

According to analyst recommendations, Indoco Remedies Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app